Lichen planus

STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage

Retrieved on: 
Thursday, March 7, 2024
Lichen planus, Light therapy, Assistant, Vitiligo, Marketing, Cutaneous T-cell lymphoma, Quality of life, Senate, Atopic dermatitis, Skin, CTCL, Mycosis fungoides, CPT, Human, Light, Alopecia areata, Patient, STRATA, SSKN, Insurance, Pharmaceutical industry

The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.

Key Points: 
  • The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.
  • “Our focus extends beyond merely seeking expanded insurance coverage; we're advocating for the enhancement of patient quality of life and ensuring access to essential dermatologic treatments," stated Dr. Dolev Rafaeli, Vice Chairman and Chief Executive Officer of STRATA.
  • Over the past two months, as part of this advocacy initiative STRATA has sent over 1,000 legislative support letters to congressional and senate delegates on behalf of its patients.
  • Phototherapy has been the cornerstone of therapy for decades and remains an indispensable part of current therapy.

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

Retrieved on: 
Wednesday, December 20, 2023
Hemorrhagic cystitis, Food, LIPO, IND, FDA, Type, OLP, IRB, Tacrolimus, HC, GVHD, Growth, Lichen planus, Pharmaceutical industry

PITTSBURGH, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity.

Key Points: 
  • PITTSBURGH, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity.
  • Based in Pittsburgh, PA, the Company has made substantial strides over the past year, achieving critical milestones and advancing its pipeline with three clinical indications and two orphan drug designations granted.
  • Additionally, Lipella's LP-310 has been granted orphan drug designation for the treatment of oral graft-versus-host disease (GVHD) with tacrolimus.
  • The Company is poised to submit a Phase 2a IND for this indication in the first quarter of 2024.

ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata

Retrieved on: 
Wednesday, March 8, 2023
Janus, MD, SAN, Atopic dermatitis, AA, Hair loss, Skin, KOL, IP, Granuloma annulare, ASLN, Yale University, Scalp, JAK, Vitiligo, Yale School of Medicine, Patient, Associate, Autoimmune disease, Hair, DHODH, Immune privilege, Lichen planus, Alopecia areata, Sarcoidosis, Pharmaceutical industry, Dermatology

Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.

Key Points: 
  • Farudodstat has been shown to inhibit IFN-γ secretion, reduce immune cell proliferation, and potentially protect hair follicles from IP collapse in a human AA disease model.
  • ASLAN plans to initiate a proof-of-concept study of farudodstat in AA in the second quarter of 2023.
  • A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN’s website .
  • He has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, in particular for alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, erosive lichen planus, and other disorders.

Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia

Retrieved on: 
Friday, December 2, 2022
Health, Other Health, Managed Care, General Health, Pharmaceutical, Biotechnology, Autoimmunity, Beauty, Knowledge, Inflammation, Azathioprine, Lichen planus, COVID-19, Safety, Central nervous system, Pediatrics, CMS, Ciclosporin, Atopic dermatitis, Research, Lichen, HKEX, Therapy, JAK, Ophthalmology, Hidradenitis suppurativa, Collaboration, Marketing, Security (finance), Patient, Disease, Gastroenterology, Disclosure, Partnership, MAA, AD, Annual report, Vitiligo, Pharmaceutical industry, Vaccine, Fine chemical, Cosmetics, Incyte, Dermatology

To date, we have successfully launched ruxolitinib cream (Opzelura) in atopic dermatitis and vitiligo in the United States, to help address these challenges.

Key Points: 
  • To date, we have successfully launched ruxolitinib cream (Opzelura) in atopic dermatitis and vitiligo in the United States, to help address these challenges.
  • In partnership with CMS, we believe that, if approved, ruxolitinib cream will be an innovative therapeutic option poised to also help patients and healthcare providers in Greater China.
  • We are very honored to partner with Incyte on ruxolitinib cream in Greater China and Southeast Asia.
  • Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura.

Global Pruritus Therapeutics Market Report 2022: Significant Investments in R&D Drive Continued Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Pharmaceutical, Health, Other Health, Itch, AD, Skin, Allergic contact dermatitis, Investment, Autoimmunity, Quality of life, Moisturizer, Lichen planus, Research, Market share, Disease, Therapy, Growth, Distribution, Medicine, Patient, Knowledge, Medical device

The "Pruritus Therapeutics Market By Drug type, By Disease Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pruritus Therapeutics Market By Drug type, By Disease Type, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global pruritus therapeutics market was valued at $7,849.4 million in 2021, and is projected to reach $11,186.15 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.
  • These drivers provide a favorable environment for increasing sales of pruritus products and for growth of the overall market.
  • Moreover, patent expiry of various pruritus therapeutic products provide a greater opportunity for market players to grow their business.

Olansky Dermatology & Aesthetics welcomes acclaimed physician assistant, Wayne Emineth

Retrieved on: 
Thursday, March 31, 2022
Family, Aesthetics, Shingles, Mohs surgery, Gary Emineth, Biopsy, Skin, Moles, Dermatology, Psoriasis, Suite, Skin cancer, Roswell, Mycobacterium, Dermatoscopy, Lichen planus, Abscess, MRSA, Acne, Patient, Veterinary medicine, Medical imaging

ATLANTA, March 31, 2022 /PRNewswire-PRWeb/ -- Olansky Dermatology & Aesthetics – Atlanta's premier full-service dermatology practice – prides itself on amassing a roster of outstanding dermatologic providers. This tradition continues as the practice welcomes Wayne Emineth, an acclaimed physician assistant with more than 30 years of dermatology experience.

Key Points: 
  • ATLANTA, March 31, 2022 /PRNewswire-PRWeb/ -- Olansky Dermatology & Aesthetics Atlanta's premier full-service dermatology practice prides itself on amassing a roster of outstanding dermatologic providers.
  • This tradition continues as the practice welcomes Wayne Emineth, an acclaimed physician assistant with more than 30 years of dermatology experience.
  • "Olansky Dermatology & Aesthetics is a standout among the city's healthcare landscape," says Emineth.
  • "Accomplished physician assistants are invaluable," says Dr. Jodi Ganz, managing partner of Olansky Dermatology & Aesthetics.

Worldwide Photopheresis Products Industry to 2029 - Key Drivers, Challenges and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 11, 2021
Biotechnology, Health, Medical Devices, Autoimmunity, Scleroderma, GVHD, T-cell lymphoma, US Foods, Incidence, ECP, Patient, Food, Atopic dermatitis, National Institute, NIEHS, Photopheresis, Death, Blood, CTL, Graft-versus-host disease, Lupus erythematosus, Research, Asia, National Institute of Environmental Health Sciences, Transplant, UVA, Autoimmune disease, Female, Crohn's disease, Degenerative disease, Population, Lichen planus, Government, Woman, Pharmaceutical industry, Vaccine

The US Food and Drug Administration has approved photopheresis, commonly known as extracorporeal photopheresis (ECP), for the treatment of cutaneous T-cell lymphoma.

Key Points: 
  • The US Food and Drug Administration has approved photopheresis, commonly known as extracorporeal photopheresis (ECP), for the treatment of cutaneous T-cell lymphoma.
  • This report covers all the quantitative aspects of the Photopheresis Products Market and also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.
  • A rise in the number of organ transplant patients is predicted to increase the demand for photopheresis products.
  • However, on other hand, due to the high cost of ECP therapy, the global market for photopheresis products may experience a slowdown.

CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical Officer

Retrieved on: 
Thursday, May 13, 2021
Organ systems, Lichen planus, Internal medicine, Medical school, Medicine, Medical specialties

Kim has over 20 years of drug development experience most recently serving as Chief Medical Officer of clinical-stage biotech company Afyx Therapeutics, where he led clinical, medical and regulatory development for Rivelin, a novel mucoadhesive patch to deliver treatment for diseases such as oral lichen planus.

Key Points: 
  • Kim has over 20 years of drug development experience most recently serving as Chief Medical Officer of clinical-stage biotech company Afyx Therapeutics, where he led clinical, medical and regulatory development for Rivelin, a novel mucoadhesive patch to deliver treatment for diseases such as oral lichen planus.
  • He has also served as an Assistant Professor and Chief Endocrine Fellow at the University of California, San Diego School of Medicine.\nDr.
  • Kim received his medical degree from The Chicago Medical School and completed his internal medicine residency at Rush University Medical College.
  • CymaBay disclaims any obligation to update these forward-looking statements except as required by law.\n"

Study Published in the European Journal of Oral Sciences Features AFYX Therapeutics’ Rivelin-CLO Patch for the Treatment of Oral Lichen Planus

Retrieved on: 
Thursday, March 11, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Medical Supplies, Organ systems, Steroids, Medical specialties, Autoimmune diseases, Corticosteroids, Lichenoid eruptions, Organochlorides, Lichen planus, Clobetasol, Electrospinning, Rivelin Patch Technology, AFYX Therapeutics

This is the first study to show the successful transmucosal delivery of a corticosteroid using electrospun patch technology and confirmed that the drug delivered retained its anti-inflammatory activity.

Key Points: 
  • This is the first study to show the successful transmucosal delivery of a corticosteroid using electrospun patch technology and confirmed that the drug delivered retained its anti-inflammatory activity.
  • Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol to treat symptomatic Oral Lichen Planus (OLP) lesions.
  • This new mucoadhesive patch technology holds great promise for the treatment of patients with mucosal diseases.
  • Rivelin is a muco-adhesive two layered patch that delivers a pharmaceutical product (such as clobetasol) directly to wet tissue surfaces.

New Study Shows Promising Compounded Drug-Delivery Option for Patients with Oral Inflammatory Condition

Retrieved on: 
Monday, May 4, 2020
Health, FDA, Dental, Clinical trials, Research, Science, Pharmaceutical, Medical specialties, Organ systems, Autoimmune diseases, Lichenoid eruptions, Medicine, Lichen planus, Ulcer

Researchers have completed a pilot study that shows promise for patients with oral lichen planus (OLP), a condition that can result in a burning sensation, pain and ulcers in the mouth, announced PCCA.

Key Points: 
  • Researchers have completed a pilot study that shows promise for patients with oral lichen planus (OLP), a condition that can result in a burning sensation, pain and ulcers in the mouth, announced PCCA.
  • View the full release here: https://www.businesswire.com/news/home/20200504005653/en/
    OLP is a chronic inflammatory condition caused by the bodys immune system attacking tissues in the mouth.
  • The study tested the tolerability and effectiveness of a compounded oral steroid solution compared with a standard solution in a group of 20 adults who had been diagnosed with OLP.
  • However, this study provides preliminary data on a promising drug-delivery option for patients with OLP.